A new study shows that it is possible to selectively target and block a particular microRNA that is important in liver cancer. The findings might offer a new therapy for this malignancy, which kills an estimated 549,000 people worldwide annually. The study focused on miR-221, which is consistently present at abnormally high levels in human liver cancer. The treatment significantly prolonged survival in an animal model and promoted the activity of important tumor-suppressor genes.